Latest Breaking News On - Jamesc mullen - Page 1 : comparemela.com

Form N-PX CAPITAL MANAGEMENT INVES For: Jun 30

Form N-PX CAPITAL MANAGEMENT INVES For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDanielf akersonGeorges barrettDeborah flintStephenf angelJames bellScottm sperlingBrucea carlsonLaurenced finkLynnm bamfordKathleen wilsonBruced hoechnerSherrym smithJosephf dunford jrLucase watsonDouglasm baker jr

Why Shares of Editas Medicine Rose Monday

The company is benefiting from positive news affecting other gene-editing stocks.

Jamesc mullenGemma reeveInstitute for clinicalVertex pharmaceuticalsEditas medicineEconomic review

Editas Medicine (EDIT) Appoints Emma Reeve to its Board

Editas Medicine (EDIT) Appoints Emma Reeve to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Jamesc mullenGilmore oneillAton pharmaGemma reeveBroad instituteHarvard university casExchange commissionIntrepid allianceInotek pharmaceuticalsParexel internationalBroad institute casEditas medicine incYale collegeInstitute of chartered accountantsBoard of omega therapeutics incUniversity of london

Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director

Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 Editas. | April 13, 2023

United kingdomGemma reeveAton pharmaJamesc mullenGilmore oneillTherapeutics incYale school of medicineAadi bioscience incIntrepid allianceConstellation pharmaceuticals incBoard of trusteesInstitute of chartered accountantsParexel internationalTufts medical centerBoard of omega therapeutics incUniversity of london

Editas Medicine (EDIT) Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

Editas Medicine (EDIT) Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJamesc mullenEditas medicine incDrug administrationWall streetOrphan drug designationRare pediatric diseaseChief executive officerDrug designation